- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06387745
Referral of Patients to Hepatology With Hepatoscope (US-REFERRAL)
Use of Ultrasound Tools to Refer Patients at Risk of Chronic Liver Disease to the Hepatology Consultation (US-REFERRAL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic liver diseases (CLD) remain asymptomatic for a long time, until they become decompensated (cirrhosis) or lead to liver cancer. CLD all have a very similar natural history: over several years, or even tens of years, liver fibrosis develops progressively, which leads to cirrhosis and the related risks of complications of cirrhosis, including portal hypertension, liver failure, of even liver cancer.
In the absence of complications, liver fibrosis and cirrhosis remain completely symptomatic. For this reason, several methods for the non-invasive assessment of liver fibrosis have been developed over the last 20 years, with the objective to screen for liver fibrosis in it early stage so as to manage the patient and potentially prevent to development of complications. There are 2 groups of such noninvasive methods: blood-based tests and methods that measure the liver stiffness, which is directly correlated to liver fibrosis severity.
There are simple blood tests such as the FIB-4 and others can be more complex like FibroTest.
The FIB-4 test, which takes into account 4 parameters easily available (age, platelets, and 2 liver enzymes, AST and ALT), is very useful in the general population because of its high negative predictive value. However, it is mainly used for the diagnosis of liver fibrosis in the context of chronic viral hepatitis.
The measurement of liver stiffness is currently available on a hepatology-dedicated device, the FibroScan, or on high-end ultrasound imaging systems that are available in radiology centers. This measurement of liver stiffness has demonstrated excellent performances for the diagnosis of cirrhosis and a good performance for the assessment of liver fibrosis severity at earlier stages. However, in clinical practice, this method is not widely available nor accessible (cost of equipment of limited to radiology centers).
For the diagnosis of liver steatosis (excess of fat accumulation in the liver), which can also lead to liver fibrosis, cirrhosis and its complications, the Gold Standard exam that can quantify the extent of fat in the liver is Magnetic Resonance Imaging derived Proton Density Fat Fraction (MRI PDFF), but its use in routine is extremely limited due to the lack of MRI equipment, their cost, and the cost of MRI exams. Liver steatosis can be assessed with ultrasound imaging systems (in radiology) and also with FibroScan, although the interpretation of exam results remains variable.
In primary care, in diabetology-endocrinology and in the hepatology practice, it is now known that the screening of chronic liver diseases at their early stages is of paramount importance for a proper management of patients. New simple, available and affordable tools are urgently needed to cover the territory and assess patients at risk where they are, at the point of care, during consultations.
This clinical trial will assess the performance of an ultra-portable, point-of-care ultrasound device for the assessment of liver fibrosis and steatosis in the primary care setting, to optimize referral of patients to the tertiary hepatology consultation for further specialist investigation.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Luisa Vonghia, MD, PhD
- Phone Number: +32 038213659
- Email: luisa.vonghia@uza.be
Study Contact Backup
- Name: Sven Francque, MD, PhD
- Phone Number: +32 038214572
- Email: sven.francque@uza.be
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with any of the following
- Elevated liver enzymes (AST, ALT, Gamma-GT, AP)
- Type 2 diabetes
- Elements of metabolic syndrome
- Patients who consent in written to participate in the Clinical Investigation after being orally informed on the objectives and methods of the Clinical Investigation
Exclusion Criteria:
- Patients with active implants such as pacemakers, defibrillators, pumps, etc.
- Patients presenting wounds at the location where the Hepatoscope probe shall be placed on patients' skin,
- Pregnant and breastfeeding women,
- People deprived of their freedom rights.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Investigational Arm
Single arm study protocol
|
The Hepatoscope is a non-invasive external ultrasound imaging device, intended for general purpose pulse echo ultrasound imaging, and soft tissue elasticity imaging of the human body.
In addition, the Hepatoscope provides measurements of shear wave speed and tissue stiffness, ultrasound beam attenuation and estimates of speed of sound, in internal structures of the body.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive Predictive Value for significant fibrosis
Time Frame: at study completion: 12 months
|
Estimation of Positive Predictive Value in percentage with 95% confidence interval for estimation of significant fibrosis.
|
at study completion: 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of stiffness measurements
Time Frame: at study completion: 12 months
|
Liver stiffness measurements performed with the device subject of the research and competitor device will be compared by analysis of correlation.
The analysis outcome will be the R² coefficient and its p value.
|
at study completion: 12 months
|
Concordance of stiffness measurements
Time Frame: at study completion: 12 months
|
Liver stiffness measurements performed with the device subject of the research and competitor device will be compared by analysis of concordance.
The analysis outcome will be the Concordance Correlation Coefficients (CCC) and 95% confidence intervals.
|
at study completion: 12 months
|
Diagnostic performance of liver stiffness measurements
Time Frame: at study completion: 12 months
|
Area under the receiver operating characteristic (ROC) curve will be used an a general assessment of diagnostic performance against dichotomized population according to referral outcome.
Diagnostic estimators in the studied population will be derived from the ROC analysis: sensitivity, specificity, positive and negative predictive values.
|
at study completion: 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Luisa Vonghia, MD, PhD, University Hospital, Antwerp
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- US-REFERRAL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Liver Disease
-
First Affiliated Hospital of Zhejiang UniversityCompletedAcute-On-Chronic Liver Failure | Cirrhosis and Chronic Liver Disease
-
Chuncheon Sacred Heart HospitalSuspendedChronic Liver Disease | Acute Derangement of Liver FunctionKorea, Republic of
-
Assiut UniversityCompletedAcute-On-Chronic Liver FailureEgypt
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnLiver Failure, Acute on ChronicChina
-
Beijing 302 HospitalShenzhen Third People's Hospital; Shulan (Hang Zhou) Hospital; BeijingYouan Hospital and other collaboratorsRecruitingAcute-On-Chronic Liver FailureChina
-
Shanghai Jiao Tong University School of MedicineNot yet recruitingChronic Liver Disease and CirrhosisChina
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
Chulalongkorn UniversityRecruitingAcute-On-Chronic Liver Failure | Acute on Chronic Hepatic FailureThailand
-
Daewoong Pharmaceutical Co. LTD.Enrolling by invitationChronic Liver DiseaseKorea, Republic of
-
Meridian Bioscience, Inc.CompletedChronic Liver DiseaseUnited States, Israel